The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10B | Lipid modifying agents, combinations | |
| 4 | C10BX | Lipid modifying agents in combination with other drugs | |
| 5 | C10BX03 | Atorvastatin and amlodipine |
| Active Ingredient | Description | |
|---|---|---|
| Atorvastatin and Amlodipine |
Combination of two drugs, a dihydropyridine calcium channel blocker, amlodipine, and an HMG-CoA reductase inhibitor, atorvastatin. The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CADUET Film-coated tablet | Marketing Authorisation Holder | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
